日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1

阿来替尼通过抑制程序性死亡配体1 (PD-L1) 增强二唾液酸神经节苷脂2嵌合抗原受体T细胞在ALK突变型神经母细胞瘤中的抗肿瘤疗效。

Sugitatsu, Yuya; Tomida, Akimasa; Suematsu, Masaya; Inoue, Tomoya; Kubo, Hiroshi; Nakazawa, Yozo; Yagyu, Shigeki; Iehara, Tomoko

Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell Carcinoma

EPHB4-CAR-T细胞瘤内注射治疗口腔鳞状细胞癌的可行性研究

Ito, Yusuke; Suzuki, Toshihiro; Shimomura, Manami; Takenouchi, Kazumasa; Ohnuki, Kazunobu; Shoda, Kayoko; Kenmochi, Yuka; Yagyu, Shigeki; Matsuura, Kazuto; Hayashi, Ryuichi; Nakatsura, Tetsuya

Ligand-Based CAR-T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies.

靶向 EGFR 的配体 CAR-T 细胞对妇科恶性肿瘤表现出良好的抗肿瘤效果

Shinagawa Manaka, Hirabayashi Koichi, Fujioka Marina, Kamijo Kyosuke, Uchiyama Natsuki, Yokokawa Yusuke, Tanaka Yasuhiro, Ono Motoki, Chinsuwan Thanyavi, Asaka Ryoichi, Hasegawa Aiko, Tanaka Miyuki, Murakami Takashi, Yagyu Shigeki, Miyamoto Tsutomu, Shiozawa Tanri, Nakazawa Yozo

Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr)

正在进行的试验:针对表达EPHB4受体的恶性实体瘤的非病毒基因修饰CAR-T细胞疗法的I期研究(CARTiEr)

Funasaka, Chikako; Naito, Yoichi; Kubota, Hitomi; Ishiguro, Yukiko; Fuse, Nozomu; Wakabayashi, Masashi; Sato, Akihiro; Yuda, Junichiro; Ishii, Genichiro; Suzuki, Toshihiro; Takenouchi, Kazumasa; Nakatsura, Tetsuya; Morita, Konomi; Inada, Yoichi; Tanaka, Miyuki; Nakazawa, Yozo; Yagyu, Shigeki; Doi, Toshihiko

Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer

胃癌中肿瘤抑制因子miR-5193血液水平低下可作为PD-L1免疫治疗的靶点

Kamiya, Hajime; Komatsu, Shuhei; Takashima, Yusuke; Ishida, Ryo; Arakawa, Hiroshi; Nishibeppu, Keiji; Kiuchi, Jun; Imamura, Taisuke; Ohashi, Takuma; Shimizu, Hiroki; Arita, Tomohiro; Konishi, Hirotaka; Shiozaki, Atsushi; Kubota, Takeshi; Fujiwara, Hitoshi; Yagyu, Shigeki; Iehara, Tomoko; Otsuji, Eigo

Erratum: Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers

更正:基于配体、piggyBac 工程化的靶向 EGFR 的 CAR-T 细胞对非小细胞肺癌安全有效。

Chinsuwan, Thanyavi; Hirabayashi, Koichi; Mishima, Shuji; Hasegawa, Aiko; Tanaka, Miyuki; Mochizuki, Hidemi; Shimoi, Akihito; Murakami, Takashi; Yagyu, Shigeki; Shimizu, Kimihiro; Nakazawa, Yozo

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function

由PiggyBac转座子介导的CD19嵌合抗原受体T细胞来源于CD45RA阳性外周血单核细胞,具有强效且持久的抗白血病功能。

Suematsu, Masaya; Yagyu, Shigeki; Nagao, Nobuyoshi; Kubota, Susumu; Shimizu, Yuto; Tanaka, Miyuki; Nakazawa, Yozo; Imamura, Toshihiko

Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma

开发非病毒性、配体依赖性、EPHB4特异性嵌合抗原受体T细胞用于治疗横纹肌肉瘤

Kubo, Hiroshi; Yagyu, Shigeki; Nakamura, Kayoko; Yamashima, Kumiko; Tomida, Akimasa; Kikuchi, Ken; Iehara, Tomoko; Nakazawa, Yozo; Hosoi, Hajime

Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype

自体抗原呈递细胞可有效扩增以记忆表型为主的 piggyBac 转座子 CAR-T 细胞

Nakamura, Kayoko; Yagyu, Shigeki; Hirota, Shogo; Tomida, Akimasa; Kondo, Makoto; Shigeura, Tomokuni; Hasegawa, Aiko; Tanaka, Miyuki; Nakazawa, Yozo

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma

抑制MEK通路可增强嵌合抗原受体T细胞对神经母细胞瘤的抗肿瘤疗效

Tomida, Akimasa; Yagyu, Shigeki; Nakamura, Kayoko; Kubo, Hiroshi; Yamashima, Kumiko; Nakazawa, Yozo; Hosoi, Hajime; Iehara, Tomoko